Overview of Efalizumab Placebo- controlled Phase III Trials

July 1, 2003

Efalizumab is a humanized IgG monoclonal antibody directed against the alpha chain of LFA-1 (CD11a) expressed on the surface of T cells.11 Efalizumab blocks the interaction between LFA-1 and ICAM-1 on APCs, vascular endothelial cells, and cells in the dermis and epidermis.